00:00The president said it's a triumph for the American patient. Is it?
00:05So like most of these most favored nations deals that Trump is doing with drug companies,
00:11you know, we don't know the full fine details of this yet. The basic parameters,
00:15you know, are similar to other deals that Trump has done so far with companies like Pfizer or
00:19AstraZeneca. This is kind of the obesity drug deal that Trump is doing. They're talking about
00:25prices being offered starting for some Medicare patients with certain conditions is $245 a month
00:32with a $50 copay. And then for Lilly's drug, $299 for the lowest dose. And so what we don't know is
00:40will all Medicare plans have to cover it. So there's just a lot of like details we don't know yet,
00:45but this is definitely a win for Eli Lilly and Nova Nordisk to get these deals with administration
00:51that spares them from terrorists for three years. And both companies have also gotten a special
00:56priority review voucher from the FDA for their new pale obesity drugs. It'll enable those to get to
01:02the market faster in exchange for offering them at lower cash prices. So the company's got something
01:07out of it today. So, you know, it's a win, but how much overall for how many people this lowers prices,
01:12you know, as remains to be seen. Yeah. Bob, how does it compare to a number of the other deals we've
01:17seen the Trump administration strike with, call it Pfizer or other drug manufacturers?
01:23Yeah, the basic outlines are similar. So the companies agree for medicines going forward to
01:28adopt most favorite, for new medicines going forward to adopt most favorite nation pricing,
01:32where they want to price it higher in the U.S. than other wealthy nations. They agree to,
01:38you know, offer lower prices to Medicaid and offer some low prices on, you know, Trump Rx,
01:46this new platform for direct cash purchases at lower prices. So it's kind of a similar format
01:52that they've done. What we don't have is full parameters, you know, how it all kind of nets
01:57out how much money will be saved and how many more people, you know, really will get access to lower
02:01prices that don't have it now, because there are a lot of people that are insured and get good prices
02:05now and don't need this. So how many people will go through these other platforms? You know, for this
02:09one, I think one of the biggest questions is like, you know, how many more people starting next year
02:14in Medicare, that's the government program, the elderly will have eligibility to get these
02:20obesity drugs, you know, at lower prices that it's not available at all now yet. And that's like not
02:24totally clear yet. They're having a briefing in a couple hours with more details on those plans,
02:29but they're talking about $245 a month for obesity shots in Medicare for certain patients also of other
02:36conditions besides obesity, like prediabetes and heart conditions.
02:41Well, that's what I wanted to ask next. If you think through the costs of the U.S. health care
02:46system, you think through the potential savings, if a patient who, you know, has prediabetes or is at
02:52risk of heart failure, being on a weight loss drug could actually save the government more down the
02:57road, whether they're a Medicare or Medicaid. How is that factoring into kind of at least your sources
03:03thinking through lower prices for some of these people with comorbidities?
03:06Yeah, we just don't know the details of how this Medicaid care program is going to work yet. Like,
03:13for example, Medicare right now, Medicare prescription drugs, you know, that goes through
03:17individual plans and they differ from plan to plan. And right now under law, obesity,
03:23pure obesity isn't allowed to be covered at all now under law. But they are talking about expanding
03:29this like the people with obesity, but have certain other conditions treated by the drugs, you know,
03:34like prediabetes. And so with the fine details, we just don't have them yet. So like, you know,
03:41how widely available they'll be and how many people really will have access to these drugs at this
03:45lower price, we just don't know yet.
Comments